drugset

drugset / Trial / NCT03485547

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT03485547 ↗

Phase 1 Completed 5 enrolled Dana-Farber Cancer Institute AbbVie · collab

NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax

Timeline

Start: 2018-08-23
Primary completion: 2022-01-10
Completion: 2025-04-16

Publications

Wang SY, Thomassen K, Kurch L, Opitz S, Franke GN, Bach E, Platzbecker U, Kayser S. Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e579-e582. doi: 10.1016/j.clml.2021.02.008. Epub 2021 Mar 2. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Venetoclax	Small molecule	—	Oral

Indications